Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Straumann Holding AGXSWX:STMN +0.68%97 Cash-to-Debt is 1.17 as of Dec. 2025, which is 17% above its 10-year median of 1.00. GuruFocus rates XSWX:STMN with a GF Score™ of 97/100 and a GF Value™ of CHF138.01 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 848 Medical Devices & Instruments companies, Straumann Holding AG ranks worse than 56.6% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Straumann Holding AG's cash to debt ratio for the quarter that ended in Dec. 2025 was 1.17.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Straumann Holding AGcould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Straumann Holding AG's Cash-to-Debt or its related term are showing as below:
XSWX:STMN'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.58 Med: 1 Max: 1.4
Current: 1.17
During the past 13 years, Straumann Holding AG's highest Cash to Debt Ratio was 1.40. The lowest was 0.58. And the median was 1.00.
XSWX:STMN's Cash-to-Debt is ranked worse than 56.6% of 848
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs XSWX:STMN: 1.17
Straumann Holding AG (XSWX:STMN) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Straumann Holding AG Cash-to-Debt Related Terms
Straumann Holding AG Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:STMN vs ISRG, BDX, MDLN: Cash-to-Debt Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG (XSWX:STMN) has a Cash-to-Debt of 1.17 as of Dec. 2025. This is 17% above median its historical median of 1.00. Over the past decade, Straumann Holding AG's Cash-to-Debt has ranged from 0.58 to 1.40. According to the industry distribution chart, Straumann Holding AG ranks #480 out of 848 companies in the Medical Devices & Instruments industry, placing it in the top 56.6%.
Is Straumann Holding AG's Cash-to-Debt too high?
Straumann Holding AG's current Cash-to-Debt of 1.17 is 17% above median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 1.40. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Straumann Holding AG's value of 1.17 is 28.7% below this industry median. Based on the distribution chart, Straumann Holding AG ranks #480 out of 848 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Straumann Holding AG has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #480 out of 848 companies for Cash-to-Debt. This places Straumann Holding AG in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Straumann Holding AG's value of 1.17 is 28.7% below this benchmark. Historically, Straumann Holding AG's own Cash-to-Debt has ranged from 0.58 to 1.40 over the past decade. While the company's 10-year median is 1.00 vs. the industry median of 1.64, Straumann Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 848 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current Cash-to-Debt of 1.17 is 28.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current Cash-to-Debt is 1.17, which is 17% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF138.01, compared to a current price of CHF102.90 — trading 25.4% below its estimated fair value. The current Cash-to-Debt is 1.17, which is 17% above median its 10-year median of 1.00 and 28.7% below the Medical Devices & Instruments industry median of 1.64. Straumann Holding AG's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current Cash-to-Debt is 1.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF102.90 is trading 25.4% below its estimated GF Value™ of CHF138.01.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
Cash-to-Debt: 1.17 (17% above median its 10-year median of 1.00)
GF Value™: CHF138.01 vs. price of CHF102.90 (25.4% below fair value)
Industry Position: 28.7% below the Medical Devices & Instruments median (#480 of 848)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
97GF Score
Get the complete analysis for XSWX:STMN
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
